Study COVID-19 infection in people after organ or bone marrow transplant
Part of Infections, Lungs & breathing clinical trials.
This study looks at how common COVID-19 (SARS-CoV-2) infection is and what outcomes happen in people who have had a transplant. It may help doctors understand what to expect and how to better support transplant patients during COVID-19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a solid organ transplant or a bone marrow (hematopoietic cell) transplant at UZ Leuven
- You are 18 years or older
- You are willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well transplant patients understand the information they receive about infection risks. It aims to improve this educational material.
This study looks at what happens when people with kidney transplants get COVID-19. It may help improve how doctors monitor and manage COVID-19 in transplant recipients.
This study looks at how lung function changed over time in lung transplant patients who had a moderate to severe COVID-19 infection. It may help doctors understand how to better care for transplant patients after a serious COVID-19 illness.
This trial follows people who have had a recent organ or stem cell transplant to learn more about infections and how they can be prevented. You may be asked to provide samples and information over time.
This study looks at how well vaccines work in people who have received a bone marrow or solid organ transplant. Researchers will track infections and outcomes to understand vaccine effectiveness.
This study looks at COVID-19 in people who have (or have had) blood cancers and are positive for SARS‑CoV‑2. It may help doctors understand how COVID-19 affects people with blood cancers and guide care.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.